Regen BioPharma (Regen BioPharma) FCF Margin % : -354.24% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Regen BioPharma's Free Cash Flow for the three months ended in Mar. 2024 was $-0.21 Mil. Regen BioPharma's Revenue for the three months ended in Mar. 2024 was $0.06 Mil. Therefore, Regen BioPharma's FCF Margin % for the quarter that ended in Mar. 2024 was -354.24%.

As of today, Regen BioPharma's current FCF Yield % is -20.16%.

The historical rank and industry rank for Regen BioPharma's FCF Margin % or its related term are showing as below:

RGBP' s FCF Margin % Range Over the Past 10 Years
Min: -1721.82 Med: -621.35 Max: 17.27
Current: -203.81

During the past 11 years, the highest FCF Margin % of Regen BioPharma was 17.27%. The lowest was -1721.82%. And the median was -621.35%.

RGBP's FCF Margin % is ranked worse than
54.4% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs RGBP: -203.81

Regen BioPharma FCF Margin % Historical Data

The historical data trend for Regen BioPharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma FCF Margin % Chart

Regen BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

FCF Margin %

Get a 7-Day Free Trial

-438.18

17.27

-661.40

-257.20

-73.42

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-89.83	-147.46	-38.98	-274.58	-354.24

Competitive Comparison of Regen BioPharma's FCF Margin %

For the Biotechnology subindustry, Regen BioPharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's FCF Margin % falls into.

Regen BioPharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Regen BioPharma's FCF Margin for the fiscal year that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-0.174	/	0.237
	=	-73.42 %

Regen BioPharma's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-0.209	/	0.059
	=	-354.24 %

Regen BioPharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.